$SRRK

AKKARAJU SRINIVAS purchased $12.0M of SRRK (indirect holdings)

AKKARAJU SRINIVAS purchased 289,470 indirectly-held shares of Scholar Rock Holding Corp (SRRK) at an average of $41.45 ($41.31–$41.82, $12.00M total) across 6 trades over 2026-10-23 to 2026-10-26.

Original reporting
SEC EDGAR · AKKARAJU SRINIVAS
Published Oct 27, 2026, 11:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SRRK
Bullish
high confidence
Mentioned
$SRRK
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SRRKBullishMed
01

Why it matters

The $12M purchase by a director is a fresh, primary disclosure that can influence short‑term price dynamics.

02

Market read

Direct insider buying provides a modest bullish catalyst for SRRK, potentially attracting short‑term traders.

03

What to watch

The purchase was made at a range of $41.31‑$41.82; if the stock is near resistance, the impact may be muted.

Relevance 8/10Novelty 7/10Timing: after-hours filing on Oct 27

Background

Form 4 filings disclose insider transactions; director purchases are closely watched for sentiment cues.

Company-level read

Ticker impact

$SRRKBullishHigh confidence
Context

Director Akkaraju Srinivas bought $12M of SRRK shares, increasing his stake to 723,020 shares.

Expected impact

likely upward pressure as the market prices in insider confidence

Evidence & confidence

A $12M purchase by a director is a material insider transaction that often signals positive outlook, prompting short‑term buying interest.

Market effects

May reinforce positive sentiment for biotech and life‑science service firms.

Limited to US markets where SRRK trades.

Low

Counterpoint

Insider buying could be a routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Scholar Rock Holding Corp

    US‑listed biotech services firm (ticker SRRK).

  • Akkaraju Srinivas

    Director of Scholar Rock who made the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

$SRRKMed

Raymond James reiterates Scholar Rock stock rating on MAA resubmission

Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.

$SRRKMed

Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval

Scholar Rock (SRRK) resubmitted its European application for apitegromab, a treatment for spinal muscular atrophy (SMA), after addressing a manufacturing issue. The resubmission includes a new facility and is supported by Phase 3 trial results showing motor function improvements. The EMA is expected to issue an opinion in 2027. SRRK shares are currently trading at $41.48, down 1.71%.

$SRRKMed

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (SRRK) resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) for treating spinal muscular atrophy (SMA). The resubmission includes an alternate fill-finish facility, aligning with EMA guidance. The company anticipates a CHMP opinion in H1 2027. Apitegromab, marketed as ISEMBYLD in the U.S., is the first muscle-targeted therapy to show motor function improvement in SMA patients.

$SRRKMedAI 8/10

Scholar Rock resubmits EU application for SMA treatment

Scholar Rock (NASDAQ:SRRK) resubmitted its EU application for apitegromab, a treatment for spinal muscular atrophy, using an alternate fill-finish facility. The company withdrew its previous application due to GMP compliance issues. Scholar Rock anticipates a CHMP opinion in the first half of 2027. Apitegromab is FDA-approved in the U.S. under the brand name ISEMBYLD.